Natera (NTRA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 54.39%. A quarter ago, it was expected that this genetic testing company would post a loss of $0.69 per share when it actually produced a loss of $0.30, delivering a surprise of 56.52%.Over the last four quarters, the company has s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 (State or O ...

Exhibit 99.1 Natera Reports Third Quarter 2024 Financial Results AUSTIN, Texas, November 12, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights · Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a record increase of 63.9%. Product revenues grew 64.4% o ...

The global precision medicine market size is estimated at $91.72 billion for 2024, with an 11.6% projected CAGR until 2033, and it is expected to reach $246.3 billion by 2033. This boom is largely supported by the development of technologies (i.e., next-generation sequencing and artificial Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and ...

Natera (NTRA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a changing earnin ...

I m Antines the minimal manufacturer of the many of the may be NicoElNino Thesis Natera, Inc. (NASDAQ:NTRA) is a diagnostic company focused on the development and commercialization of cell-free DNA (cfDNA) tests. The company's test can be grouped into three main health areas: women's health, organ health, and oncology. In terms of revenue, Natera's lead products are Panorama (a non-invasive prenatal genetic test aiming to identify altered genes in the fetus from the mom's blood sample) and Horizon (a carrie ...

Natera, Inc. (NASDAQ:NTRA) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Mike Brophy - CFO Steve Chapman - CEO Solomon Moshkevich - President, Clinical Diagnostics Alexey Aleshin - GM Oncology, CMO Conference Call Participants Dan Brennan - Cowen Rachel Vatnsdal - JP Morgan Puneet Souda - Leerink Partners Tejas Savant - Morgan Stanley Douglas Schenkel - Wolfe Research Tycho Peterson - Jefferies Catherine Schulte - Baird Subbu Nambi - Guggenheim Eve Burstein - Bernstein Oper ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 (State or Other ...

Natera (NTRA) reported $413.35 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 58.1%. EPS of -$0.30 for the same period compares to -$0.97 a year ago. The reported revenue represents a surprise of +21.54% over the Zacks Consensus Estimate of $340.1 million. With the consensus EPS estimate being -$0.69, the EPS surprise was +56.52%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Stre ...

Natera (NTRA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 56.52%. A quarter ago, it was expected that this genetic testing company would post a loss of $0.72 per share when it actually produced a loss of $0.56, delivering a surprise of 22.22%. Over the last four quarters, the company has ...